Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: Comparison with enhanced CT

Kazuhiro Kitajima, Koji Murakami, Erena Yamasaki, Yasushi Kaji, Ichio Fukasawa, Noriyuki Inaba, Kazuro Sugimura

研究成果: Article

117 引用 (Scopus)

抄録

Purpose: The purpose of the study is to evaluate the accuracy of integrated positron emission tomography and computed tomography (PET/CT) with 18F-fluorodeoxyglucose (FDG) with IV contrast for preoperative staging of ovarian cancer, in comparison with enhanced CT, using surgical and histopathological findings as the reference standard. Materials and methods: Forty patients with ovarian cancer underwent FDG-PET/contrast-enhanced CT scans for staging before primary debulking surgery. PET/CT and the CT component separately, were interpreted by two experienced radiologists by consensus for each investigation. Status with regard to lesion inside and outside the pelvis was determined on the basis of histopathology. The significance of differences between the two imaging modalities was determined using the McNemar test. Results: Staging revealed stage I in 18 patients (IA, n=9; IB, n=3; IC, n=6), stage II in seven (IIA, n=2; IIB, n=3; IIC, n=2), stage III in 14 (IIIA, n=1; IIIB, n=3; IIIC, n=10), and stage IV in one. The results of CT and PET/CT were concordant with the final pathological staging in 22 out of 40 (55%) and 30 out of 40 (75%) cases, respectively. The overall lesion-based sensitivity improved from 37.6% (32 out of 85) to 69.4% (59 out of 85), specificity from 97.1% (578 out of 595) to 97.5% (580 out of 595), and accuracy from 89.7% (610 out of 680) to 94.0% (639 out of 680) between CT and PET/CT. There were significant differences in sensitivity and accuracy, with p values of 5.6×10 -7 and 1.2×10-7, respectively. Conclusion: Integrated FDG-PET/contrast-enhanced CT is a more accurate imaging modality for staging ovarian cancer and useful for selecting appropriate treatment than enhanced CT.

元の言語English
ページ(範囲)1912-1920
ページ数9
ジャーナルEuropean Journal of Nuclear Medicine and Molecular Imaging
35
発行部数10
DOI
出版物ステータスPublished - 2008 10
外部発表Yes

Fingerprint

Ovarian Neoplasms
Fluorodeoxyglucose F18
Pelvis
Positron Emission Tomography Computed Tomography
Therapeutics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

これを引用

Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer : Comparison with enhanced CT. / Kitajima, Kazuhiro; Murakami, Koji; Yamasaki, Erena; Kaji, Yasushi; Fukasawa, Ichio; Inaba, Noriyuki; Sugimura, Kazuro.

:: European Journal of Nuclear Medicine and Molecular Imaging, 巻 35, 番号 10, 10.2008, p. 1912-1920.

研究成果: Article

Kitajima, Kazuhiro ; Murakami, Koji ; Yamasaki, Erena ; Kaji, Yasushi ; Fukasawa, Ichio ; Inaba, Noriyuki ; Sugimura, Kazuro. / Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer : Comparison with enhanced CT. :: European Journal of Nuclear Medicine and Molecular Imaging. 2008 ; 巻 35, 番号 10. pp. 1912-1920.
@article{4b3af36bd4624361a6c1035fdb133fdc,
title = "Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: Comparison with enhanced CT",
abstract = "Purpose: The purpose of the study is to evaluate the accuracy of integrated positron emission tomography and computed tomography (PET/CT) with 18F-fluorodeoxyglucose (FDG) with IV contrast for preoperative staging of ovarian cancer, in comparison with enhanced CT, using surgical and histopathological findings as the reference standard. Materials and methods: Forty patients with ovarian cancer underwent FDG-PET/contrast-enhanced CT scans for staging before primary debulking surgery. PET/CT and the CT component separately, were interpreted by two experienced radiologists by consensus for each investigation. Status with regard to lesion inside and outside the pelvis was determined on the basis of histopathology. The significance of differences between the two imaging modalities was determined using the McNemar test. Results: Staging revealed stage I in 18 patients (IA, n=9; IB, n=3; IC, n=6), stage II in seven (IIA, n=2; IIB, n=3; IIC, n=2), stage III in 14 (IIIA, n=1; IIIB, n=3; IIIC, n=10), and stage IV in one. The results of CT and PET/CT were concordant with the final pathological staging in 22 out of 40 (55{\%}) and 30 out of 40 (75{\%}) cases, respectively. The overall lesion-based sensitivity improved from 37.6{\%} (32 out of 85) to 69.4{\%} (59 out of 85), specificity from 97.1{\%} (578 out of 595) to 97.5{\%} (580 out of 595), and accuracy from 89.7{\%} (610 out of 680) to 94.0{\%} (639 out of 680) between CT and PET/CT. There were significant differences in sensitivity and accuracy, with p values of 5.6×10 -7 and 1.2×10-7, respectively. Conclusion: Integrated FDG-PET/contrast-enhanced CT is a more accurate imaging modality for staging ovarian cancer and useful for selecting appropriate treatment than enhanced CT.",
keywords = "F-FDG, Ovarian cancer, PET/CT, Staging",
author = "Kazuhiro Kitajima and Koji Murakami and Erena Yamasaki and Yasushi Kaji and Ichio Fukasawa and Noriyuki Inaba and Kazuro Sugimura",
year = "2008",
month = "10",
doi = "10.1007/s00259-008-0890-2",
language = "English",
volume = "35",
pages = "1912--1920",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer

T2 - Comparison with enhanced CT

AU - Kitajima, Kazuhiro

AU - Murakami, Koji

AU - Yamasaki, Erena

AU - Kaji, Yasushi

AU - Fukasawa, Ichio

AU - Inaba, Noriyuki

AU - Sugimura, Kazuro

PY - 2008/10

Y1 - 2008/10

N2 - Purpose: The purpose of the study is to evaluate the accuracy of integrated positron emission tomography and computed tomography (PET/CT) with 18F-fluorodeoxyglucose (FDG) with IV contrast for preoperative staging of ovarian cancer, in comparison with enhanced CT, using surgical and histopathological findings as the reference standard. Materials and methods: Forty patients with ovarian cancer underwent FDG-PET/contrast-enhanced CT scans for staging before primary debulking surgery. PET/CT and the CT component separately, were interpreted by two experienced radiologists by consensus for each investigation. Status with regard to lesion inside and outside the pelvis was determined on the basis of histopathology. The significance of differences between the two imaging modalities was determined using the McNemar test. Results: Staging revealed stage I in 18 patients (IA, n=9; IB, n=3; IC, n=6), stage II in seven (IIA, n=2; IIB, n=3; IIC, n=2), stage III in 14 (IIIA, n=1; IIIB, n=3; IIIC, n=10), and stage IV in one. The results of CT and PET/CT were concordant with the final pathological staging in 22 out of 40 (55%) and 30 out of 40 (75%) cases, respectively. The overall lesion-based sensitivity improved from 37.6% (32 out of 85) to 69.4% (59 out of 85), specificity from 97.1% (578 out of 595) to 97.5% (580 out of 595), and accuracy from 89.7% (610 out of 680) to 94.0% (639 out of 680) between CT and PET/CT. There were significant differences in sensitivity and accuracy, with p values of 5.6×10 -7 and 1.2×10-7, respectively. Conclusion: Integrated FDG-PET/contrast-enhanced CT is a more accurate imaging modality for staging ovarian cancer and useful for selecting appropriate treatment than enhanced CT.

AB - Purpose: The purpose of the study is to evaluate the accuracy of integrated positron emission tomography and computed tomography (PET/CT) with 18F-fluorodeoxyglucose (FDG) with IV contrast for preoperative staging of ovarian cancer, in comparison with enhanced CT, using surgical and histopathological findings as the reference standard. Materials and methods: Forty patients with ovarian cancer underwent FDG-PET/contrast-enhanced CT scans for staging before primary debulking surgery. PET/CT and the CT component separately, were interpreted by two experienced radiologists by consensus for each investigation. Status with regard to lesion inside and outside the pelvis was determined on the basis of histopathology. The significance of differences between the two imaging modalities was determined using the McNemar test. Results: Staging revealed stage I in 18 patients (IA, n=9; IB, n=3; IC, n=6), stage II in seven (IIA, n=2; IIB, n=3; IIC, n=2), stage III in 14 (IIIA, n=1; IIIB, n=3; IIIC, n=10), and stage IV in one. The results of CT and PET/CT were concordant with the final pathological staging in 22 out of 40 (55%) and 30 out of 40 (75%) cases, respectively. The overall lesion-based sensitivity improved from 37.6% (32 out of 85) to 69.4% (59 out of 85), specificity from 97.1% (578 out of 595) to 97.5% (580 out of 595), and accuracy from 89.7% (610 out of 680) to 94.0% (639 out of 680) between CT and PET/CT. There were significant differences in sensitivity and accuracy, with p values of 5.6×10 -7 and 1.2×10-7, respectively. Conclusion: Integrated FDG-PET/contrast-enhanced CT is a more accurate imaging modality for staging ovarian cancer and useful for selecting appropriate treatment than enhanced CT.

KW - F-FDG

KW - Ovarian cancer

KW - PET/CT

KW - Staging

UR - http://www.scopus.com/inward/record.url?scp=52449111259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52449111259&partnerID=8YFLogxK

U2 - 10.1007/s00259-008-0890-2

DO - 10.1007/s00259-008-0890-2

M3 - Article

C2 - 18682935

AN - SCOPUS:52449111259

VL - 35

SP - 1912

EP - 1920

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 10

ER -